Piramal Pharma Limited (PPLPHARMA) Stock Forecast & Price Target

Compare

10 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

PPLPHARMA Analyst Ratings

Moderate Buy

1 Buy

0 Hold

0 Sell

Based on 1 analysts giving stock ratings to

Piramal

Pharma Limited

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

PPLPHARMA Stock 12 Month Forecast

Average Price Target

₹305.00

▲(58.32% Upside)

Based on 1 Wall Street analysts offering 12 month price targets for Piramal Pharma Limited in the last 3 months. The average price target is ₹305.00 with a high forecast of ₹305.00 and a low forecast of ₹305.00. The average price target represents a 58.32% change from the last price of ₹192.65.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"186":"₹186","216":"₹216","246":"₹246","276":"₹276","306":"₹306"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹305.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹305.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":305,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹305.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[186,216,246,276,306],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Mar<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.3,207.43076923076924,215.56153846153848,223.6923076923077,231.82307692307694,239.95384615384617,248.0846153846154,256.2153846153846,264.34615384615387,272.4769230769231,280.60769230769233,288.73846153846154,296.86923076923074,{"y":305,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.3,207.43076923076924,215.56153846153848,223.6923076923077,231.82307692307694,239.95384615384617,248.0846153846154,256.2153846153846,264.34615384615387,272.4769230769231,280.60769230769233,288.73846153846154,296.86923076923074,{"y":305,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,199.3,207.43076923076924,215.56153846153848,223.6923076923077,231.82307692307694,239.95384615384617,248.0846153846154,256.2153846153846,264.34615384615387,272.4769230769231,280.60769230769233,288.73846153846154,296.86923076923074,{"y":305,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":228.6,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":268.23,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":272.77,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":257.98,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":232.75,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":189.83,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":189.83,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":225.45,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":210.91,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":204.47,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":190.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":187.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":199.3,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target₹305.00

Average Price Target₹305.00

Lowest Price Target₹305.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Alankar Garude

Kotak Mahindra

₹305

Buy

58.32%

Upside

Reiterated

09/29/25

Kotak Mahindra Reaffirms Their Buy Rating on Piramal Pharma Limited (PPLPHARMA)

Dhawal Khut

Jefferies

₹260

Buy

34.96%

Upside

Initiated

08/25/25

Jefferies Assumes Piramal Pharma (PIRPHARM:IN) at BuyJefferies analyst Dhawal Khut assumes coverage on Piramal Pharma (PIRPHARM:IN) with a Buy rating and a price target of INR260.00.

Shyam Srinivasan

Goldman Sachs

₹265→₹250

Buy

29.77%

Upside

Reiterated

07/15/25

Piramal Pharma Limited (PPLPHARMA) Gets a Buy from Goldman Sachs

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Alankar Garude

Kotak Mahindra

₹305

Buy

58.32%

Upside

Reiterated

09/29/25

Kotak Mahindra Reaffirms Their Buy Rating on Piramal Pharma Limited (PPLPHARMA)

Dhawal Khut

Jefferies

₹260

Buy

34.96%

Upside

Initiated

08/25/25

Jefferies Assumes Piramal Pharma (PIRPHARM:IN) at BuyJefferies analyst Dhawal Khut assumes coverage on Piramal Pharma (PIRPHARM:IN) with a Buy rating and a price target of INR260.00.

Shyam Srinivasan

Goldman Sachs

₹265→₹250

Buy

29.77%

Upside

Reiterated

07/15/25

Piramal Pharma Limited (PPLPHARMA) Gets a Buy from Goldman Sachs

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Piramal Pharma Limited

1 Month

xxx

Success Rate

1/2 ratings generated profit

Average Return

+0.95%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +0.95% per trade.

3 Months

xxx

Success Rate

0/3 ratings generated profit

Average Return

-9.40%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 0.00% of your transactions generating a profit, with an average return of -9.40% per trade.

1 Year

Alankar GarudeKotak Mahindra

Success Rate

0/2 ratings generated profit

Average Return

-17.25%

reiterated a buy rating 3 months ago

Copying Alankar Garude's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -17.25% per trade.

2 Years

xxx

Success Rate

0/2 ratings generated profit

Average Return

-17.25%

reiterated a xxx

rating 3 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -17.25% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PPLPHARMA Analyst Recommendation Trends

Rating

May 25

Jul 25

Aug 25

Sep 25

Oct 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, PPLPHARMA has received 2 Buy Ratings, 7 Hold Ratings, and 0 Sell Ratings. PPLPHARMA average Analyst price target in the past 3 months is 305.00.

Each month's total comprises the sum of three months' worth of ratings.

PPLPHARMA Financial Forecast

PPLPHARMA Earnings Forecast

Next quarter’s earnings estimate for PPLPHARMA is ₹0.20 with a range of ₹0.20 to ₹0.20. The previous quarter’s EPS was -₹0.70. PPLPHARMA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year PPLPHARMA has Performed in-line its overall industry.

PPLPHARMA Sales Forecast

Next quarter’s sales forecast for PPLPHARMA is ₹23.35B with a range of ₹22.70B to ₹24.00B. The previous quarter’s sales results were ₹20.44B. PPLPHARMA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year PPLPHARMA has Performed in-line its overall industry.

PPLPHARMA Stock Forecast FAQ

What is IN:PPLPHARMA’s average 12-month price target, according to analysts?

Based on analyst ratings, Piramal Pharma Limited’s 12-month average price target is 305.00.

What is IN:PPLPHARMA’s upside potential, based on the analysts’ average price target?

Piramal Pharma Limited has 58.32% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Piramal Pharma Limited a Buy, Sell or Hold?

Piramal Pharma Limited has a consensus rating of Moderate Buy, which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.

What is Piramal Pharma Limited’s share price target?

The average share price target for Piramal Pharma Limited is 305.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is ₹305.00 ,and the lowest forecast is ₹305.00. The average share price target represents 58.32% Increase from the current price of ₹192.65.

What do analysts say about Piramal Pharma Limited?

Piramal Pharma Limited’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.

How can I buy shares of Piramal Pharma Limited?

To buy shares of IN:PPLPHARMA, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Piramal Pharma Limited (PPLPHARMA) Stock Forecast & Price Target

PPLPHARMA Analyst Ratings

PPLPHARMA Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Piramal Pharma Limited

PPLPHARMA Analyst Recommendation Trends

PPLPHARMA Financial Forecast

PPLPHARMA Earnings Forecast

PPLPHARMA Sales Forecast

PPLPHARMA Stock Forecast FAQ

Detailed List of Analyst Forecasts